ASSOCIATION OF MALAT1 RS3200401 GENE POLYMORPHISM WITH KIDNEY CANCER IN UKRAINIAN POPULATION

A. D. Volkogon; A. A. Roshchupkin; Ya. D Chumachenko; V. Yu. Harbuzova; A. V. Ataman

A. D. Volkogon Sumy State University, 2 Rimskogo-Korsakova str, Sumy, Ukraine, 40007
A. A. Roshchupkin Sumy State University, 2 Rimskogo-Korsakova str, Sumy, Ukraine, 40007
Ya. D Chumachenko Sumy State University, 2 Rimskogo-Korsakova str, Sumy, Ukraine, 40007
V. Yu. Harbuzova Sumy State University, 2 Rimskogo-Korsakova str, Sumy, Ukraine, 40007
A. V. Ataman Sumy State University, 2 Rimskogo-Korsakova str, Sumy, Ukraine, 40007

Keywords: MALAT1, long non coding RNA, single nucleotide polymorphism, renal cell carcinoma.

Abstract

Introduction. As it is known, only 2 % of the human genome encodes proteins, while the greater part of the genome corresponds to non-coding sequences. In the recent years among a large variety of non-coding sequences special attention of researchers was drawn to long non-coding RNA MALAT1. This sequence first was detected in 2003 in non-small cell lung cancer cells. Today the results of numerous experiments revealed that MALAT1 is one of the major genes involved in various types of cancer, including kidney cancer.

Purpose. To study the association between MALAT1 rs3200401 polymorphism and kidney cancer development in Ukrainian population.

Materials and methods. 101 patients with kidney cancer (renal cell carcinoma) was enrolled into the study. The final diagnosis was based on anamnesis data, clinical, biochemical and instrumental examinations according to the recommendations of European Association of Urology. All participants were treated in the hospital of Sumy Regional Oncology Center. The control group included 100 healthy individuals without personal cancer history. The study of MALAT1 rs3200401 SNP was perfprmed by Real-time PCR using 7500 Fast Real-time PCR System (Applied Biosystems, Foster City, USA) and Taq-Man Assays (TaqMan®SNP Assay C_3246069_10). Statistical analyses were performed using Statistical Package for Social Science software (SPSS, version 17.0, Chicago, IL, USA) and online resource “SNIPKA”.

Results. The distribution of CC-homozygotes, CT-heterozygotes and TT-homozygotes in patients with kidney cancer was 71 (70.3%), 29 (28.7 %) and 1 (0.99 %), respectively. In the control group, distribution of genotypes was 59 (59.0 %), 32 (32.0 %) and 9 (9.0 %), respectively. The significant difference in genotypes distribution between kidney cancer patients and the control group was found (P = 0.022). Genotypic analysis has shown that T-minor allele carriers had less risk of kidney cancer development compared to patients with CC-genotype (P = 0.031, OR = 0.101, 95 % CI = 0.013–0.814).

Conclusion. There is statistically significant link between MALAT1 rs3200401 polymorphism and kidney cancer development in Ukrainian population. Individuals with minor T-allele (TT- and CT-genotypes) have less risk of renal cell carcinoma development compared to major homozygotes (CC).

Downloads

Download data is not yet available.

References

1. Ewan A Gibb, Carolyn J Brown, Wan L Lam. The functional role of long non-coding RNA in human carcinomas. Carolyn Mol Cancer. 2011; 10: 38. doi: 10.1186/1476-4598-10-38.
2. Hirata H, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75:1322–1331. doi: 10.1158/0008-5472.CAN-14-2931.
3. John N Hutchinson, et al. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007; doi: 10.1186/1471-2164-8-39.
4. Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al. 2003. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031–8041. doi:10.1038/sj.onc.1206928.
5. Xian-Yong Ma, Jian-Hui Wang, Jing-Lan Wang, Charles X Ma, Xiao-Chun Wang, and Feng-Song Liu. MALAT1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genomics. 2015; 16(1): 676. doi: 10.1186/s12864-015-1881-x.
6. Ming Li, Ying Wang, Liang Cheng, Wanting Niu, Guoan Zhao, Jithin K. Raju, Jun Huo, Bin Wu, Bo Yin, Yongsheng Song, and Renge Bu. Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. Oncotarget. 2017 Jul 18; 8(29): 48424–48435. doi: 10.18632/oncotarget.17053.
7. Elizabeth M. Smigielski, Karl Sirotkin, Minghong Ward, and Stephen T. Sherry. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000 Jan 1; 28(1): 352–355. doi: 10.1093/nar/28.1.352.
8. Zhang HM, Yang FQ, Chen SJ, Che J, Zheng JH. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour Biol. 2015 Apr;36(4):2947-55. doi: 10.1007/s13277-014-2925-6.
9. Qian Li, et al. The MALAT1 gene polymorphism and its relationship with the onset of congenital heart disease in Chinese. Biosci Rep. 2018 Jun 29; 38(3): BSR20171381. doi: 10.1042/BSR20171381
10. Genan Wang, Yaxiong Li, Yong Peng, Jian Tang and Hua Li. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids in Health and Disease (2018) 17:75. doi: 10.1186/s12944-018-0728-2
11. Wang JZ, et al. A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis. BMC Cancer. 2017 Mar 3;17(1):167. doi: 10.1186/s12885-017-3151-6.
12. Peng R, Luo C, Guo Q, Cao J, Yang Q, Dong K, Wang S, Wang K, Song C. Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene. 2018 Feb 5;642:241-248. doi: 10.1016/j.gene.2017.11.013.